openPR Logo
Press release

Meet with over 120 senior early drug developers to discuss maximising drug investments, toxicology, safety and biomarkers

10-23-2012 07:53 PM CET | Health & Medicine

Press release from: World Trade Group

The Early Drug Development Summit is taking place on 3rd-4th December 2012 at the Hotel Palace Berlin, Germany and attracts Europe's most senior early drug developers together to meet, network, and learn.

Debate about smart deployment of drug development processes and platform technologies to help maximise new product value and increase the likelihood of new drugs being approved by regulators quickly.

Participating in pre-arranged one-to-one meetings, benchmarking and sharing strategies on optimising drug development trajectory whilst network with industry professionals about improving strategies in toxicology and biomarkers this is the must attend summit for all industry experts.

Key focus points on this year’s programme include:

Maximising Drug Investments -
• Maximising investment to reduce risk and cost of early drug development
• Optimising decision making in early drug development- prioritising the best investments
Toxicology & Safety -
• Using predictive pharmaceutical modelling to predict a compound’s SAR profile
• Applying predictive and simulation modelling in preclinical development
Biomarkers -
• Accelerating clinical trials using predictive humanised animal models
• Utilising biomarkers to bridge the gap between preclinical and clinical trials

What our delegates had to say:

Meet the right companies and people. Fantastic time management — Astra Zeneca

Excellent opportunity to benchmark business excellence strategies with both small and large companies — Head Production, Biopharmaceutical Operations Huningue, Novartis

An excellent opportunity to glimpse the mind set and processes of other pharmaceutical companies — Teva Pharmaceutical Industries

For more information please contact Michaela Melcher, Marketing Manager on +44(0)20 7202 7690 or email michaela.melcher@wtgevents.com

About WTG: http://www.worldtradegroup.com/

World Trade Group (WTG) is a leading global integrated media company. Operating within the sectors of HR, energy, pharmaceutical, food and beverage, manufacturing and supply chain, we organise and run some of the leading annual business events, bringing together senior executives from world class organisations.

Michaela Melcher
90 Union Street
SE1 0NW London
United Kingdom

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Meet with over 120 senior early drug developers to discuss maximising drug investments, toxicology, safety and biomarkers here

News-ID: 239891 • Views: 1807

More Releases from World Trade Group

Award-winning speakers are meeting at the Global Pharma Manufacturing Summit 201 …
Event dates and location: 8th Annual Global Pharma Manufacturing Summit 2013 June 27th-28th 2013 The Westin Copley Place, Boston, US www.gpmsummit.com Now in its eighth year, the Global Pharma Manufacturing Summit presents premier networking opportunities for pharma manufacturing industry leaders to discuss and share their expertise. Over 150 senior executives and decision-makers will spend two days in June to discuss best practices about quality management, manufacturing excellence, outsourcing and contract manufacturing. Manufacturers are facing increasing
WTG Launching Smart Grids Asia Summit in Singapore
Event dates and location: Smart Grids Asia Summit 25th-26th June 2013 Singapore www.smartgridsummitasia.com WTG’s best energy conference award-winner Smart Grids event is coming to Asia. Building on the success of recent smart grids summits in Europe, WTG is pleased to announce the launch of the Smart Grids Asia Summit on 25th-26th June 2013 in Singapore. According to the latest reports, the global smart grid market will be worth US$24.1 billion, with China, Japan and South Korea
The programme for the 4th Annual Food Manufacturing & Safety Summit is now being …
This food and beverage industry summit is taking place on 11th-12th February 2013 at Grand Hotel Huis ter Duin Noordwijk, Netherlands. Meet with over 150 senior food and beverage professionals from across Europe to discuss the improvements of productivity, achieve continuous improvement and maximise food safety and quality whilst reducing costs. Speaker announcement - Karl Douglas, Lean Director at Carlsberg will be presenting a wider approach to lean throughout production, logistics and
LNG Experts Gathering at WTG’s 7th Annual LNG Tech Global Summit 2012
World Trade Group is organising the 7th Annual LNG Tech Global Summit between 3rd and 5th December 2012 in Rotterdam, Netherlands. This is the leading technical industry conference for anyone involved at any stage of the LNG supply chain, namely liquefaction or regasification facilities, LNG shippers, technology providers and relevant governing bodies. The event is endorsed by the Gas LNG Europe (GLE) Association. LNG Tech Global Summit presents a combination of

All 5 Releases


More Releases for Drug

Biologics Drug Discovery Market
2019-2025 Biologics Drug Discovery Market Report with Depth Analysis The biologics drug discovery involves target identification, hit-to-lead stage, lead identification and optimization. The report presents a comprehensive overview, market size, shares, and growth opportunities of Biologics Drug Discovery market by product type, application, key manufacturers and key regions. Request For Free report Sample -https://www.reportsmonitor.com/request_sample/306320 Scope of the Report: Furthermore, Biologics Drug Discovery Market report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers or
Opioid Antagonist Drug Market
The global market has been prognosticated to earn demand from popular types of products such as external use, oral and applications such as household and hospital. The Company has made available another publication in its Healthcare archive of market intelligence reports, which is titled “Global Opioid Antagonist Drug Market Research Report 2018.” While the threat of substitutes and technological risks could have an unfavorable impact on the global market, potential
Drug and cosmetics
Drug and Cosmetics Conferences regards each one of the individuals to go to the On “Drug and Cosmetics” amidst October 17-October 18, 2018 in Toronto, Canada which melds brief keynote presentations, speaker talks, Exhibition, Symposia, Workshops. Drug and Cosmetics Congress is one of the meetings and conferences which will be visited by all the prestigious cosmetologists, Scientists, fiery inspectors, postgraduates, affiliations, business meanders under a solitary rooftop. DRug and cosmetics BLESSY MATHEW Program
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning